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Rationale: Patients with fatal asthma have been hypothesized as representing two distinct
subgroups according to the onset of symptoms prior to death.
Objectives: To determine if these two groups may be reliably identified and determine if they
differ clinically and pathologically.
Methods: Patients with autopsies, 2e34 years of age, dying from asthma were classified slow-onset
(Type 1) or rapid-onset (Type 2). The consistency of classification by two independent observerswas
determined. Clinical and pathologic data was compared between groups.
Main results: Among37 subjects therewere 21Type 1and 16Type2mortalities. Inter-observer agree-
mentwasgood;k0.63 (95%CI0.38,0.87). Subjectsdidnotdifferbyage, race, sex,presenceofobesity,
insurance status, or use of corticosteroids. Type 1mortalitieswere hospitalizedmore (2.5þ 1.3 versus
0.1þ 0.1;pZ 0.048)andmademoreemergencyroomvisits (10.5þ 4.9versus0.8þ 0.2;pZ 0.023) in
the year prior to death than Type 2 mortalities. At autopsy, bronchial eosinophils (p< 0.025) and
bronchiolar basement membrane thickening (p< 0.05) were more predominant in Type 1 mortalities
compared with Type 2. Airway wall neutrophils were uncommon in both groups.
Conclusion: Good inter-observer agreement exists in classifying patients dying from asthma according
towhether theonset of symptomswas slowor rapid in onset. Slow-onset patients had a predominance
of eosinophils and basement membrane thickening and higher health care utilization. These
differences support the validity of classifying asthma mortalities into these distinct subgroups.
Published by Elsevier Ltd.936 5201; fax: þ1 734 936 5048.
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1820 R.C. Hyzy et al.Introduction claims, emergency response, medical examiner reports andPatients with severe asthma vary according to age, onset of
disease, resistance to corticosteroid therapy, presence of
chronic airflow limitation and the predominance of eosin-
ophils in the airway.1e3 In addition, the phenotype of
patients with a fatal or near-fatal asthma exacerbation
has been hypothesized to vary according to the duration
of symptoms prior to presentation.4 Patients who develop
symptoms within a few hours of presentation are reported
to have fewer infectious and more noxious inhalation
precipitants as well as more neutrophils in their airways
relative to eosinophils. In contrast, patients who have had
a longer duration of symptoms prior to presentation are
characterized as having infectious precipitants and by
eosinophilic inflammation.5e7
Studies examining the time of onset of symptoms among
fatal or near-fatal asthmatic episodes have utilized several
time points to differentiate subgroups including less or
greater than 6 h8; less or greater than 3 h9; and less than 3
or greater than 8 h.6 In patients dying from asthma, classi-
fication can be impeded by the inability to question the pa-
tient and the subsequent need to rely on other observers.
Patients with fatal asthma or near-fatal episodes are
characterized by widespread mucous plugging of airways
with secretions that are difficult to clear.10,11 Whether
every patient dying from asthma has mucous plugging at
the time of death, or that some have so-called ‘‘dry
airways’’ and are a characterized by a sudden asphyxic ep-
isode without mucous plugging remains controversial.7,12,13
Examining if reliably identifiable differences exist in the
population of patients with fatal or near-fatal episodes of
asthma would enhance the understanding of asthma by
suggesting the possible presence of more than one
pathophysiologic mechanism.7,14,15 We classified a cohort
of patients who died from asthma and had autopsies per-
formed as either slow- or rapid-onset of symptoms to death
and compared the demographic, clinical and histopatho-
logic features of these two groups of patients in order to
further explore validity of the classification of patients
into these two categories.
Methods
Funding for the demographic and clinical components of
this study was provided by the Michigan Department of
Community Health (MDCH) and the Centers for Disease
Control (CDC Cooperative Agreement U59/CCU517742).
Residents of the State of Michigan who died from asthma
(ICD-10 codes J45 or J46) between 2 and 34 years of age
over a 2-year period were identified from a database
maintained by the MDCH Division of Vital Records and
Health Statistics. CDC funding specified that only adults
under the age 35 years should be evaluated in order to more
clearly identify asthma as a cause of death. Death certif-
icates for these individuals were obtained and a letter was
sent to the next-of-kin requesting an interview.
Interviews were conducted at the home of the patient’s
next-of-kin using a standardized questionnaire. We
reviewed all available medical records from the year prior
to death, as well as any available information on pharmacyautopsy records. Autopsy slides were requested from all
subjects who had an autopsy. A summary of the medical
records and circumstances surrounding the death was
prepared for each individual. All medical records and slides
were kept in a confidential manner. This study was
approved by the Institutional Review Board of the Univer-
sity of Michigan Medical Center.
Classification of asthma deaths
Two expert asthma clinicians (R.C.H., K.D.R.) reviewed the
case materials and independently classified the deceased
according to whether the onset of symptoms leading to the
individual’s death had begun less than 6 h (Type 2 asthma
mortality) or greater than 6 h (Type 1 asthma mortality)
prior to death.16 Following the initial classification, discrep-
ancies in classification were adjudicated by the clinicians
and a final consensus was agreed upon.
Demographic comparison
Demographic information was abstracted from the records
and next-of-kin interviews pertaining to the status of the
deceased at the time of death. Information abstracted
included age, sex, race, whether the deceased was obese,
the last grade completed by the deceased, whether the
deceased died in hospital, whether the deceased had
health insurance, whether the deceased had ever seen an
asthma specialist, smoking history, use of either inhaled or
oral steroids, the presence of psychological factors, the
number of emergency room visits in the year prior to death,
and the number of hospitalizations in the year prior to
death.
Obesity was defined as either a body mass index above
30 kg/m2, in patients 18 years of age or older, or at or above
the 95% predicted body weight for patients less than 18
years of age. The last grade completed was counted numer-
ically for grades 1e12, with a 0 for patients not yet in
school and a 1 added for each year of college. Asthma spe-
cialists included either allergists or pulmonologists. The
presence of psychological factors included at least one of
the following: family dysfunction, history of depression or
other major psychological illness, history of substance
abuse, or positive toxicology screen at the time of presen-
tation with fatal asthma.
Autopsy analysis
The autopsy slides of the lung specimens were obtained
from the medical examiners office of each county where an
asthma mortality had occurred during the study time
period. Slides were analyzed by a lung pathologist
(W.D.T.) who was blinded as to the prior classification of
asthma mortality (Type 1 or Type 2) by the two expert
clinicians based on clinical history. The number of slides per
patient, and the number of bronchi and bronchioles
examined for each patient were tabulated.
Each individual pathologic feature on the slides was
evaluated using a semi-quantitative four point scale, where
0Z absent, 1Z few, 2Zmoderate amount, and 3Z large
Differences between slow- and rapid-onset deaths in asthma 1821amount. Features scored included bronchial neutrophils,
bronchiolar neutrophils, bronchial eosinophils, eosinophilic
bronchiolitis, mucous plugging, mucosal constriction, bron-
chial narrowing, bronchial wall thickening, bronchiolar lu-
men constriction, basement membrane thickening,
bronchiolar basement membrane thickening, and smooth
muscle hyperplasia. Specimens were also scored for other
histopathologic findings including lymphocytes, plasma
cells, mast cells, alveolar neutrophil, bronchiectasis, lym-
phatic dilatation, vascular congestion, goblet cell hyperpla-
sia, squamous metaplasia, submucosal gland hypertrophy,
peribronchial fibrosis, submucosal fibrosis, chronic bron-
chiolitis, bronchiolectasis, bronchiolar goblet cell hyperpla-
sia, respiratory bronchiolitis, and non-caseating granuloma.
Specimens in which a specific pathologic finding was unable
to be determined were labeled indeterminate.
Statistical analysis
A k coefficient for inter-rater agreement regarding the
classification of Type 1 or Type 2 exacerbation by the
pulmonary physicians was done using SAS (SAS software,
version 9.1; SAS Institute, Cary, NC). Unpaired t-tests,
Fisher’s exact tests, and Chi-square tests were used to
compare information for patients with Type 1 or Type 2
exacerbations as appropriate. The ManneWhitney U-test
was used to compare the number of emergency room
visits and hospitalizations between groups. For analysis
of histopathologic features the presence versus absence
of the features scored (score 0 versus score 1, 2, and 3)
and whether the findings were absent to few (score 0,
and 1) or moderate to many (score 2, and 3) were com-
pared for Type 1 and Type 2 exacerbations by Chi-square.
A p-value of <0.05 was determined to be statistically
significant.
Results
During the 48-month study period there were 288 individ-
uals identified whose cause of death was listed as asthma.
Of these, 59 (20.9%) were between 2 and 34 years of age.
Twenty three (8%) were children between 2 and 18 years of
age. The remaining 36 individuals (12.5%) were young
adults ages 19e34 years.
An autopsy was not performed in 13 of the 59 patients. In
another eight patients no tissue was available from the
autopsy. The remaining 38 patients, in whom autopsy tissue
was available, constitute the study population analyzed in
this report. The next-of-kin of five patients was unavailable
for interview, including one patient who was determined to
be unclassifiable due to insufficient clinical information.
This patient was excluded from further analysis. The
asthma clinicians initially agreed on the classification of
31 out of the 37 cases (81.1%) in whom a classification could
be made. The k coefficient for inter-rater agreement was
0.63 (95% CI 0.38, 0.87). After adjudication and obtaining
a consensus classification, 21 patients were classified as
Type 1 asthma mortalities and 16 as Type 2. All patients
were felt to have suffered death from asthma, no cases of
suspected anaphylaxis were found among the study
population.Demographic and clinical data
Type 1 patients had more hospitalizations and ER visits in
the year preceding death (Table 1). Type 1 patients aver-
aged 10.5 4.9 ER visits, compared with only 0.8 0.2
(pZ 0.023) in Type 2 patients and 2.5 1.3 hospitalizations
versus 0.1 0.1, respectively (pZ 0.048). A similar propor-
tion of patients in each group was pronounced dead in the
ER of a hospital (76.2% and 75% for Type 1 and Type 2,
respectively).
Age, sex, race or the presence of obesity were similar
among patients with Type 1 and Type 2 presentations. Over
half of Type 1 patients were male (61.9%), compared with
less than half among Type 2 patients (43.8%) (pZ 0.19). The
majority of patients in both groups were African-American.
Althoughmore than half of patients aged 18 or lesswere clas-
sified as Type 2mortalities, comparedwith fewer than half of
patients over 18, this difference was not statistically signifi-
cant (age 18, Type 1Z 5, Type 2Z 7; age> 18, Type
1Z 16 and Type 2Z 9; c2Z 1.65, p 0.20). Obesity was
present in about half of the patients (52.6% Type 1; 50%
Type 2). The rate of cigarette smoking and the presence of
psychological factors did not differ between groups.
Insurance coverage and treatment patterns were similar
between patientswith Type 1 and Type 2 presentations. Most
patients in each group had medical insurance (66.7% and
87.5% for Type 1 and Type 2, respectively). Ten of 18 Type 1
patients were on either inhaled steroids (nZ 2), oral ste-
roids (nZ 3), or both (nZ 5), similar to 10 of 15 Type 2 pa-
tients who were receiving steroids (one oral steroids, seven
inhaled steroids and two both). Data regarding steroids use
was unavailable in three Type 1 and one Type 2 patients.
Only around half of patients in each group in whom data
was available had ever seen an asthma physician.Autopsy data
Approximately the same amount of pathologic material was
available and examined for Type 1 and Type 2 patients.
Typical specimens from a Type 1 and a Type 2 patients are
presented in Fig. 1. The number of lung pathology slides
available for review was 4.75 0.48 for Type 1 patients
and 5.69 0.87 for Type 2 (pZ 0.46). In addition, the num-
ber of bronchi and bronchioles examined per patient did
not differ. Type 1 patients had an average of 9.6 1.6 bron-
chi and 45.6 6.4 bronchioles examined compared with
9.2þ 1.6 bronchi and 47.0þ 9.0 bronchioles examined in
Type 2 patients (pZ 0.74 and 0.79, respectively).
Bronchial eosinophils were more prominent among Type
1 than Type 2 patients. Bronchial eosinophils were present
in all Type 1 patients but were absent in 4 of 15 (26.6%) of
Type 2 patients. In addition 13 of 20 (65%) of Type 1
patients had a moderate of large number of eosinophils,
compared with only 4 of 15 (26.6%) Type 2 patients.
Bronchial eosinophilia correlated positively with basement
membrane thickening, bronchial wall thickness, and
smooth muscle hyperplasia (data not shown). The histo-
pathologic analysis is listed in Table 2.
In general, neutrophils were not prominent and did not
differentiate between Type 1 and Type 2 mortalities. Eighty
four percent of all patients (31/37) had either few or no
Table 1 Comparison of demographic information between
Type 1 and Type 2 asthma deaths
Variable Type 1 Type 2 p-Value
Number 21 16
Age 25.0 8.8 21.8 7.0 pZ 0.22
Sex
Male 13 7 pZ 0.33
Female 8 9
Race
White 9 5 pZ 0.19
Black 12 10
Other 0 1
Obesity
Present 10 8 pZ 1
Absent 9 8
Unknown 2 0
Last grade completed
Mean 10.8 3.5 10.6 2.6 pZ 0.81
Median 12 12
Died at hospital
Yes 16 12 p< 1
No 5 4
Possessed medical insurance
Yes 12 14 pZ 0.23
No 6 2
Unknown 3 0
Seeing an asthma physician
Yes 6 6 pZ 1
No 7 5
Unknown 8 5
On inhaled or oral steroids
Yes 10 10 pZ 0.72
No 8 5
Unknown 3 1
ER visits in year prior
Mean (nZ number
of patients)
10.5þ 4.9
(nZ 14)
0.8þ 0.2
(nZ 14)
pZ 0.023
Median 2 1
Hospitalized in year prior
Mean (nZ number
of patients)
2.5þ 1.3
(nZ 13)
0.1þ 0.1
(nZ 14)
pZ 0.048
Median 1 0
Active cigarette smoker
Yes 6 3 pZ 0.44
No 11 12
Unknown 4 1
Psychological factors present
Yes 8 6 pZ 1
No 10 7
Unknown 3 3
1822 R.C. Hyzy et al.bronchial or bronchiolar neutrophils. Neutrophils were
absent from the bronchi of 62% (23/37) patients and the
bronchioles of 87.1% (27/37) patients.
Mucous plugging did not differ between Type 1 and Type
2 mortalities. Mucous plugging was absent (score 0) in four
patients, one Type 1 patient and three Type 2 patients. In
these four patients, the average number of bronchi exam-
ined was 6.2 2.2 per patient (mean SEM) and bronchi-
oles 72.8 22.6 (mean SEM). However, 3 of the 4 with
patients with no mucous plugging and 7 of the 12 patients
scored as having limited mucous plugging (score 1) were
described as having mucous plugs or abundant mucus in
their autopsy report.Discussion
The results of this study confirm that slow-onset (Type 1)
and rapid-onset (Type 2) asthma mortalities represent two
distinct subgroups of patients. These subgroups were
consistently identified on the basis of their clinical pre-
sentation and differed in terms of health care utilization
and histopathologic findings. Slow-onset patients are char-
acterized by greater health care utilization, greater bron-
chial eosinophilia and more bronchial basement membrane
thickening. In subjects where mucous plugging was scarce
or absent, re-examination of the gross description by the
medical examiner revealed significant mucous plugging had
been present, suggesting the concept of ‘‘dry airways’’ is
may be an artifact introduced by tissue processing and does
not differentiate between groups.
The classification of patients with fatal or near-fatal
episodes of asthma into slow-onset or rapid-onset can be
difficult owing to the potential unreliability of clinical
information available. Patients with near-fatal episodes
tend to underestimate the duration of their attack.17 The
inability to question patients with fatal asthmatic episodes
can render it difficult to ascertain with precision exactly
when symptoms began. As a result, studies of asthma
deaths comparing slow-onset and rapid-onset groups may
be unduly influenced by problems in classification.
Previous studies of fatal asthma have not specified
whether any inter-observer variability was present in
classifying patients. Our study used two expert asthma
clinicians to classify patients independent of one another,
using 6 h of symptoms as the dividing line between rapid-
onset and slow-onset presentation. We found a good degree
of agreement between observers, with a k correlation coef-
ficient of 0.63 (95% CI 0.38, 0.87). Hence, despite the lack
of patient availability for direct questioning, patients with
fatal asthma episodes can be consistently differentiated
into discrete groups based on the clinical presentation
obtained from others. This consistency lends credence to
the clinical and histopathologic differences observed in
this study between these groups.
Severe asthma is reported to be more prevalent among
females in some,18 but not all series.19 In Michigan the ratio
of male to female deaths in the age category 2e34 is 58%e
42%. We did not observe a sex difference among asthma
mortality types: Type 1 fatal asthmatics did not manifest
an anticipated female predominance along with a male pre-
dominance among Type 2 mortalities.16 This may reflect the
Figure 1 Histologic specimens typical of Type 1 and Type 2 patients. Type 1 asthma: (A) the bronchial lumen is narrowed and
shows mucous plugging and marked submucosal gland hypertrophy (arrow) 4; (B) in addition to mucous plugging (arrow) and
submucosal gland hypertrophy, there is smooth muscle hyperplasia 10; (C) There is a thickening of the subepithelial basement
membrane and a marked inflammatory infiltrate with numerous eosinophils 20. Type 2 asthma: (A) the bronchial lumen is widely
patent and shows no mucous plugging or submucosal gland hyperplasia; (B) The bronchial lumen does not show any mucous plug and
the submucosal glands are inconspicuous. Only slight smooth muscle hyperplasia is present; (C) there is basement membrane
thickening, but minimal inflammation and no eosinophilia.
Differences between slow- and rapid-onset deaths in asthma 1823fact that our population consisted only of individuals under
the age 34 or less at the time of death. Patients who die
from asthma tend to be older and have a higher proportion
of females than patients with near-fatal asthma.20 Younger
patients who die from asthma are more evenly distributed
among males and females and may be more likely to pres-
ent sudden-onset severe asthma,21,22 especially given that
the impairment of dyspnea often seen in these patients is
more prevalent among males.23,24
A majority of patients of both groups in our series were
African-American, consistent with previous observations.25
Obesity, prevalent in severe asthma,15 was present in about
half of our population and did not differ between Type 1
and Type 2 patients. Similarly, about equal numbers of
Type 1 and Type 2 mortalities had health insurance, were
seeing an asthma physician and were on either inhaled ororal corticosteroids at the time of death, an important
risk factor for near-fatal events.26
The majority of our patients were pronounced dead at
the hospital. Rapid-onset patients were no more likely to be
pronounced dead away from the hospital. However,
although most patients died at the hospital, all had had
cardiopulmonary resuscitation either by emergency medi-
cal services en route or in the emergency room. Although
nationwide around a third of asthma deaths occur in
hospital,27 in our series no patient, in either group had
been admitted overnight to the hospital prior to death.
Patients with severe asthma have an increased rate of
health care utilization such as emergency room visits and
hospitalization.28 Increased health care utilization in
severe asthma has been associated with the presence of
psychological factors.7,29e31 Psychological problems were
Table 2 Number of asthma mortalities with pathologic findings by type of mortality and histopathologic grade
Type 1 Type 2
Histopathologic grade 0 1 2 3 NA 0 1 2 3 NA
Bronchial neutrophils 13 3 5 0 0 10 5 0 1 0
Bronchiolar neutrophils 14 3 2 2 0 13 1 1 1 0
Bronchial eosinophils 0 7 6 7 1 4 7 3 1 1
Eosinophilic bronchiolitis*,** 4 10 2 5 0 7 7 2 0 0
Mucous plugging 1 8 7 5 0 3 4 4 5 0
Mucosal constriction 4 6 6 5 0 5 6 2 2 0
Bronchial narrowing 8 5 5 2 1 6 2 5 1 1
Bronchial wall thickening 4 5 7 4 1 5 2 7 1 1
Bronchiolar lumen constriction 13 6 2 0 0 13 3 0 0 0
Bronchial basement
membrane thickening
0 1 10 9 1 0 4 7 4 1
Bronchiolar basement
membrane thickening***
8 8 2 3 0 10 6 0 0 0
Smooth muscle hyperplasia 3 6 6 5 1 1 7 6 2 0
Alveolar neutrophils 19 0 1 1 0 14 0 0 2 0
Bronchial lymphocytes 0 5 15 0 1 0 4 11 0 1
Bronchiectasis 17 1 2 0 1 10 0 5 0 2
Respiratory bronchiloitis 19 1 1 0 0 13 2 1 0 0
Peribronchial fibrosis 12 4 2 2 1 9 3 2 1 1
Submucosal fibrosis 5 10 3 3 0 1 8 5 2 0
Chronic bronchiolitis 1 9 4 7 0 1 7 8 0 0
Vascular congestion 9 1 8 3 0 4 5 7 0 0
Squamous metaplasia 17 3 1 0 0 16 0 0 0 0
Lymphatic dilitation 17 1 2 0 1 10 0 5 0 1
Goblet cell hyperplasia 1 6 8 5 1 2 5 6 3 0
Submucosal gland hyperplasia 6 7 2 5 1 1 7 5 2 1
Bronchilar goblet
cell hyperplasia
7 7 3 4 0 6 6 3 1 0
NAZ not available, unable to be assessed in patient; *p 0.025 comparing 0 versus 1, 2, and 3; **p 0.025 comparing 0 and 1 versus 2,
and 3; ***p 0.05 comparing 0 and 1 versus 2, and 3.
1824 R.C. Hyzy et al.not more prevalent among Type 1 patients. Yet, Type 1
patients manifested higher health care utilization than
Type 2 patients with a mean number of emergency room
visits and hospitalizations of 10.5 4.5 visits and 2.5 1.3
hospitalization for Type 1, as compared with 0.8 0.2 and
0.1 0.1 for Type 2, respectively.
Higher health care utilization in slow-onset patients has
not been previously reported. Health care utilization may
have been high in some Type 2 patients in whom this data
was unavailable, potentially nullifying the difference
between groups. In addition, as some of the emergency
room visits may have occurred during the terminal exacer-
bation, this difference may in part reflect an opportunity to
seek medical attention that Type 2 patients did not have.
However, that high health care users were disproportion-
ately represented among Type 1 patients suggest these
groups are not only histopathologically distinct, but
clinically distinct as well.
In a series by Kuyper mucous plugging was present in 275
airways evaluated among 93 patients, and was not observed
in five patients in whom only one or two airways were
available for review.10 Airway mucus has been reported as
being more prevalent of younger patients and in smaller
airways.32 Our series was limited to patients age 34 years
old or less and consequently it was surprising to find fourpatients in whom mucous plugging was not observed.
Among these four cases, only three had been classified as
Type 2 patient and one patient was classified Type 1
(pZ NS). In addition, more than 40% of patients in both
groups were found to have either absent or only mild
mucous plugging.
All of our cases were found to have findings consistent
with asthma at autopsy and none presented clinically with
anaphylaxis. As our cases were obtained from County
Medical Examiners we could not control for inflation of the
lung in the preparation of the specimens. The processing of
specimens could have resulted in shrinkage of mucus during
the dehydration cycle, and mucous plugs may have dropped
out during staining, serving to underestimate the presence
or extent of mucous plugging in our autopsy specimens. As
gross inspection of the autopsy specimens by the medical
examiner indicated the prevalence of mucus in all four
patients who were scored as having no mucous plugging and
in seven of 12 with only limited mucus plugging, we suggest
that the description in the medical literature of ‘‘dry
airways’’ most probably reflects an artifact introduced by
tissue processing, whenever patients dying from anaphylaxis
have not been inappropriately misclassified as asthma.
Bronchial and bronchiolar neutrophils were not more
typical of Type 2 patients as had been expected and were
Differences between slow- and rapid-onset deaths in asthma 1825not found in abundance in either group.6 The reason for this is
unclear. Previous series have shown increases in the numbers
of neutrophils in the endobronchial biopsies of both eosinophil
predominantandeosinophil non-predominant phenotypes.2,33
The prevalence of neutrophils in eosinophil non-
predominant patients potentially represents a lytic effect
on corticosteroid effect on eosinophils, leaving neutrophils
behind.15 Yet nearly equal numbers of our Type 1 and Type
2 patients were on corticosteroids in our series. As these
cells are found in the airway wall tissue processing would
be unlikely to have an impact on this finding. Hence, youn-
ger patients with fatal asthma, including both slow-onset
and rapid-onset subsets, are not necessarily characterized
by airway neutrophilia at the time of death.
Bronchial eosinophils were significantly more prevalent
among Type 1 mortalities compared with Type 2 patients.
These findings are characteristic of severe chronic
asthmatics who have onset of disease later in life.2,6 In
addition, more Type 1 patients were found to have a moder-
ate to large amount of bronchiolar basement membrane
thickening than Type 2 patients (score 2 or 3), a finding
more typical of asthmatics with fatal or near-fatal episodes
than less severe asthmatics.34 In our cohort of patients,
such evidence of basement membrane thickening suggests
the onset of airway remodeling can also be characteristic
of younger patients.
Save for the more frequent presence of bronchiolar
luminal constriction in adult patients, children did not
differ from adults histopathologically. The significance of
this is uncertain, especially in light of the fact that the
majority of adults also lacked this finding. In addition, as
basement membrane thickening did not differ between
adults and children, as might be anticipated with a poten-
tially longer duration of asthma in adults and a subsequent
greater opportunity for airway remodeling, it is unlikely
that bronchiolar luminal occlusion plays a unique role in the
demise of adults with asthma when juxtaposed with
children.
In conclusion, slow-onset (Type 1) and rapid-onset (Type
2) asthma mortalities represent consistently identifiable
subsets by the time of onset of symptoms prior to pre-
sentation. These subsets do not differ by most demographic
variables. However, health care utilization, as reflected in
emergency roomvisits and hospitalizations, is greater among
Type 1 patients. Slow-onset patients are characterized by
greater bronchial eosinophilia and more bronchial basement
membrane thickening. That patients dying from asthma can
be consistently separated into subgroups, differ by the
extent of health care utilization and have significant histo-
pathologic differences confirm that these patients represent
unique subsets and suggest that efforts focusing on the
identification of unique mechanisms of disease are valid.Conflict of interest
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